Director, Corporate Finance

Lexeo Therapeutics·
New York, New York
3w ago
Full-timeExecutiveG&A
$200K - $240K/yr(from employer)

Description

Role Summary  The Director, Corporate Finance will play an integral role in a critical function directly supporting Lexeo’s mission.  The candidate will work closely with the CFO and Controlling team to oversee all aspects of financial planning and analysis as well as capital allocation modeling related to Lexeo’s operations. The candidate must have proven ability to facilitate management dialogue and decision making through fact-based analysis and evaluation of alternatives. The role will support operational aspects, financial close, analysis, budgeting and forecasting at the program and department level. The individual will be responsible for ongoing financial management of the business and will provide the organization with decision support analysis. Additionally, the individual will support both capital markets activities and strategic financial analysis, including capital expenditures and cash forecasting. The individual will play an integral role in enabling operational success of the company’s strategic priorities and will partner across the organization to ensure transparency on financial initiatives in support of Lexeo’s objectives.   The successful candidate will leverage prior pharmaceutical / biotech industry experience, and a track record in finance to enable a culture of excellence and financial rigor. This individual is a key member of the team responsible for ensuring sufficient resource planning to meet corporate objectives with financial discipline and acts as a key advisor to the business teams with an ability to model complex operating scenarios.   We welcome applications from candidates located across the Northeast and Mid-Atlantic.
Lexeo Therapeutics

Lexeo Therapeutics

BIOTECHNOLOGY

Gene Therapy

LocationNY - New York
Open Jobs7
Gene Therapy
View Company Profile

Pipeline

A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients WiN/A
Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 PN/A
Clinical Course Of Disease In Participants With FA-CMN/A
LX1001Phase 1
LX1001Phase 1/2